Page 117 - MemoriaES-Eng

www.ciberes.org

The new methods are allowing us to unveil antigenic differences that were unde-

tected by traditional methods, such as the hemagglutination inhibition (HI) as-

say. In addition, amino acid changes associated to the noted antigenic differences
could be identified. Thus, the new methods will allow a more detailed study of the

antigenic evolution of human influenza virus.

Finally, we are also interested in the regulation of the intracellular signaling cas-

cade associated to the antiviral response triggered in RSV infected cells. Fine
modulation of these routes is essential not only to control virus replication but

also to control the inflammatory response. The activity of many of the proteins
participating in the signaling cascade is influenced by post-translational modifica-

tions, such as covalent linkage of ubiquitine or other tags (ISG15). Our results

show that the expression of certain genes involved in the innate immune re-
sponse, as well as RSV replication are regulated by these processes of ubiquitina-
á
tion and ISGylation.

í

• MAtA M, MArtíneZ i, Melero JA, tenor H, cortiJo J. Roflumilast inhibits respiratory syn-
Most relevant
cytial virus infection in human differentiated bronchial epithelial cells.PLoS One.
scientific 2013;8(7):e69670.

articles
• Melero JA, Moore Ml. Influence of respiratory syncytial virus strain differences on

pathogenesis and immunity.Curr Top Microbiol Immunol. 2013;372:59-82.

• MS V, Melero JA. Entry of enveloped viruses into host cells: membrane fusion.Subcell ú
Biochem. 2013;68:467-87.
ó

• r A, F A, c Mt, P F, g S, g-B B. Characterization
odrgueZAlconueVASoZouerrAArcíAArreno
in vitro and in vivo of a pandemic H1N1 influenza virus from a fatal case.PLoS One.
2013;8(1):e53515.

Highlights
Our group had two projects active in 2013, one of them funded by “Plan Nacional
de I+D+i” and the other funded by FIS. The results derived from both projects

were included in four international publications two of them done in collabora-

tion with other groups of “CIBER de Enfermedades Respiratorias”. Some of these
results were also included in a national patent. We are currently under negotia-

tions for exploitation of this patent. In addition, last year a license agreement was
signed with Novartis Vaccine industry, for the non-exclusive exploitation of three

monoclonal antibodies produced in our laboratory.

Several members of the group participated in the National Congress of Virology

and in the XIII International Conference on Negative Strand Viruses. Additionally,
we have participated in the evaluation of international (Germany) and national

projects (ANEP, Fundacin Andaluza Progreso y Salud). We have also participated 13
20
in national and international (Institut Pasteur) courses and masters of Virology. T
The principal investigator was awarded last year Honoris Causa Doctorate by the OR
P
“Universidad de la Repblica Oriental del Uruguay”.
RE
L
A
NU
N
A
S /
E
ER
B
CI

117